Yunnan Baiyao GroupLtd (SZSE:000538) Shareholders Have Earned a 22% Return Over the Last Year
Yunnan Baiyao GroupLtd (SZSE:000538) Shareholders Have Earned a 22% Return Over the Last Year
The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by picking above-average stocks. To wit, the Yunnan Baiyao Group Co.,Ltd (SZSE:000538) share price is 17% higher than it was a year ago, much better than the market return of around 1.9% (not including dividends) in the same period. So that should have shareholders smiling. On the other hand, longer term shareholders have had a tougher run, with the stock falling 7.3% in three years.
投資股票的最簡單方法是購買交易所交易基金。但是,通過挑選高於平均水平的股票,可以顯著提高你的回報。例如,雲南白藥集團有限公司(SZSE:000538)的股價比一年前高出17%,遠遠超過同期市場回報率約1.9%(不包括分紅派息)。所以這應該讓股東們高興。另一方面,長期股東的情況比較艱難,股票在三年內下跌了7.3%。
Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns.
讓我們看看更長期的基本面,看看它們是否與股東回報一致。
There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
不可否認的是,市場有時是有效的,但價格並不總是反映基本的業務表現。通過比較每股收益(EPS)和股價變化,我們可以了解投資者對公司的態度是如何隨時間變化的。
During the last year, Yunnan Baiyao GroupLtd actually saw its earnings per share drop 12%.
在過去一年中,雲南白藥集團有限公司的每股收益實際上下降了12%。
This means it's unlikely the market is judging the company based on earnings growth. Indeed, when EPS is declining but the share price is up, it often means the market is considering other factors.
這意味着市場不太可能根據盈利增長來評估公司。事實上,當每股收益下降而股價上漲時,往往意味着市場在考慮其他因素。
Revenue was pretty flat year on year, but maybe a closer look at the data can explain the market optimism.
營業收入同比基本持平,但也許更深入地看一下數據可以解釋市場的樂觀情緒。
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
公司的營業收入和收益(隨着時間的推移)在下面的圖像中展示(點擊查看具體數字)。

Yunnan Baiyao GroupLtd is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So we recommend checking out this free report showing consensus forecasts
雲南白藥集團有限公司是一支知名股票,擁有衆多分析師的覆蓋,這表明未來增長有一定的可見性。因此,我們建議查看這份免費的報告,以了解共識預測。
What About Dividends?
分紅派息情況如何?
When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. As it happens, Yunnan Baiyao GroupLtd's TSR for the last 1 year was 22%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!
在考慮投資回報時,重要的是要區分總股東回報(TSR)與股價回報。TSR是一個回報計算,它考慮了現金分紅的價值(假設任何收到的分紅都是再投資的)以及任何折扣資本融資和剝離的計算價值。可以說,TSR提供了更全面的股票回報情況。實際上,雲南白藥集團有限公司過去1年的TSR爲22%,超過了前面提到的股價回報。這主要是由於其分紅支付的原因!
A Different Perspective
不同的視角
It's nice to see that Yunnan Baiyao GroupLtd shareholders have received a total shareholder return of 22% over the last year. And that does include the dividend. Since the one-year TSR is better than the five-year TSR (the latter coming in at 1.1% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. It's always interesting to track share price performance over the longer term. But to understand Yunnan Baiyao GroupLtd better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Yunnan Baiyao GroupLtd .
很高興看到雲南白藥集團的股東在過去一年中獲得了總股東回報率爲22%。這其中包括分紅。在一年期的總股東回報率好於五年期的情況(後者每年爲1.1%)下,似乎該股票的表現最近有所改善。在最佳情況下,這可能暗示着一些真實的業務勢頭,這意味着現在可能是深入研究的好時機。追蹤更長期的股價表現總是有趣的。但是,要更好地了解雲南白藥集團,我們需要考慮其他很多因素。爲此,你應該注意到我們發現的雲南白藥集團的一個警告信號。
Of course Yunnan Baiyao GroupLtd may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
當然,雲南白藥集團可能不是最好的買入股票。因此你可能想查看這份免費的成長股合集。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文中引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。